Full-Time

Product Manager

Data & Operations

Posted on 9/23/2025

Progyny

Progyny

501-1,000 employees

Fertility benefits management for employers

Compensation Overview

$120k - $135k/yr

+ Bonus + Equity

No H1B Sponsorship

New York, NY, USA

Hybrid

Candidates must be based in the United States; 3 days a week in the office.

Category
Product (1)
Required Skills
Power BI
Mixpanel
Product Management
SQL
JIRA
Confluence
Data Analysis
Excel/Numbers/Sheets
Requirements
  • 4–6+ years of experience in product management for technical domains, product operations, business systems analysis, or data analysis, ideally in healthcare or another complex service environment.
  • Solid understanding of product development lifecycle and agile methodologies, with experience working closely with software engineers, data teams, and operations.
  • An Excel ninja who’s competent with SQL queries and comfortable working with data platforms (e.g., Power BI, Mixpanel).
  • Demonstrated experience mapping and modeling multi-system operational workflows and identifying opportunities for process improvement. Expertise in business process modeling notation (BPMN) is highly desirable!
  • Familiar with data modeling concepts (e.g., entity relationships, data normalization) and able to partner on designing or validating schemas that support business use cases.
  • Comfortable leading discovery and definition for technical or backend-heavy product features.
  • Strong documentation skills and familiarity with systems including MS Office, Confluence, Lucid, Miro/Mural, Jira, and the like.
  • Clear communicator who can navigate both technical detail and business context, translating between stakeholders with ease.
  • Resilient and passionate, aware that change is constant and able to adapt with a positive attitude.
Responsibilities
  • Partner with Sr. Product Managers and business stakeholders to translate operational and case management needs into clear product requirements and user stories.
  • Lead discovery and definitional efforts for data-centric features: clarify scope, reconcile data sources, address operational dependencies, and drive feature alignment across business and development teams.
  • Conduct detailed reviews and reconciliation of customer-related data sets to ensure accuracy, completeness, and trust in critical operational and product data.
  • Map data-intensive operational workflows to identify where and how data flows across systems, teams, and touchpoints, including those bridging into third-party systems as we expand our technology platform’s interoperability.
  • Facilitate technical scoping conversations with Engineering and Data stakeholders, helping evaluate feasibility, sequencing, and trade-offs.
  • Assist in developing or enhancing data models that support key product and operational workflows, ensuring data availability aligns with business needs.
  • Develop and maintain documentation including feature specs, business models and rules, data flow diagrams, workflows, and system integrations.
  • Drive data-centric features & initiatives, owning requirements, supporting sprint planning, and helping provide quality oversight.
  • Support incident reviews and post-mortems where data gaps, system issues, or workflow errors have occurred.
  • Contribute to roadmap planning and continuous improvement initiatives by identifying pain points, prioritizing solutions, and articulating value.
Desired Qualifications
  • Experience working with case management systems, contact center tooling, or third-party service platforms.
  • Exposure to APIs, microservices, data pipelines, and integration patterns.
  • Understanding of HIPAA, data governance, FHIR standards, and other healthcare compliance frameworks.
  • Background in healthtech, benefits administration, or EMR/EHR systems.

Progyny is a fertility benefits manager that partners with employers to offer comprehensive fertility and family-building services to employees. It provides a wide range of services including IUI, IVF, fertility preservation, adoption assistance, and surrogacy support, all integrated into employers’ existing benefits packages. The company makes money by signing contracts with employers, typically using a fixed-fee or per-employee-per-month pricing model, and it works to deliver better clinical outcomes to reduce overall treatment costs. Unlike broader health insurers, Progyny focuses specifically on fertility care and family-building, emphasizing measurable clinical results and seamless workflow within the benefits ecosystem. Its goal is to expand access to inclusive fertility benefits while improving outcomes and controlling costs for employers and employees.

Company Size

501-1,000

Company Stage

IPO

Headquarters

New York City, New York

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Progyny Select targets 50M small business employees for 2027 launch.
  • Q1 2026 revenue hit $328.5M, beating estimates with raised guidance.
  • Client base grew to 595 from 532 year-over-year.

What critics are saying

  • Non-renewed large client contracts limit revenue to 1.4% growth.
  • Carrot Fertility undercuts with lower-cost bundles for mid-market.
  • Stalling growth invites activist investors demanding sale within 12-18 months.

What makes Progyny unique

  • SmartCycle bundles cover full IVF cycles without lifetime caps.
  • Vets over 1,000 U.S. fertility specialists using success metrics.
  • Personal Care Advocates provide end-to-end clinical guidance.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Family Planning Benefits

Fertility Treatment Support

Wellness Program

Mental Health Support

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Yahoo Finance
Mar 21st, 2026
Progyny CEO outlines Progyny Select rollout for 2027 with IVF-only coverage and lifetime caps

Progyny CEO Pete Anevski outlined the company's utilization forecasting and the rollout of its fully insured product, Progyny Select, during a KeyBanc conference. He said the company focuses on actual benefit use rather than eligible lives counts, noting utilization has remained stable at approximately 1.03% to 1.09%. Anevski explained that Q1 consultations typically drive higher-revenue treatment activity in Q2 through Q4. The company forecasts using client history, industry patterns and where members are in their fertility journey. Progyny Select will target small-group employers through brokers and professional employer organisations, covering IVF only with lifetime caps and annual repricing to manage risk. Commercialisation begins now, but the product is expected to go live in 2027. Anevski said recent selling seasons showed no increased competition, with Progyny continuing to win "the majority of the time" against competitors.

Progyny
Mar 11th, 2026
Progyny to Participate in Inaugural HHS Women's Health Conference

Progyny to participate in inaugural HHS Women's Health conference. Company's Chief Medical Officer to present new fertility research that shows value of personalized care and treatment guidance for improving outcomes NEW YORK, March 11, 2026 - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, announced today that Chief Medical Officer Janet Choi, MD, will present new fertility research during the first annual Health and Human Services (HHS) National Conference on Women's Health, March 11-13, 2026, in Washington, DC. The event will bring together leaders across the industry to explore breakthroughs in research, prevention, diagnosis, and treatment of health conditions that affect women across the lifespan. Progyny's participation in the conference represents the company's role in contributing to and helping shape the national conversation on advancing women's health. As a recognized leader in fertility, family building, and women's health benefits, Progyny has spent the past decade partnering with employers, health plans, and clinical leaders to elevate the standard of care, improve outcomes for women and families, and advance innovation. The company has one of the largest data sets on fertility in the U.S., providing a unique ability to gather insights that can improve health outcomes. The fertility research being presented, co-authored by Alan Copperman, MD, Managing Director and CEO of RMA of New York, assessed how integrated education and clinician-guided decision-making influence treatment selection, timing, clinical outcomes, and cost of care. Key findings include: * Early cycle awareness can support informed decision-making: Nearly half of women who received early cycle-aware education did not pursue fertility treatment. * Personalized fertility care can help patients reach pregnancy more efficiently, limiting the emotional and physical toll: In this member population - where benefit design did not mandate step-protocol requirements - time to achieve a successful pregnancy in days was up to 42% shorter. * Age remains an important factor in fertility treatment success: In this analysis, only approximately 8% of IUI (intrauterine insemination) cycles were successful among patients age 35 and over, reinforcing the importance of timely evaluation and individualized care planning. * Individualized treatment decisions may help optimize birth outcomes and cost: Treatment pathways should consider the risk of multiples which can increase the likelihood of neonatal intensive care needs and associated costs. "Fertility care is highly personal and time-sensitive, and treatment decisions should reflect each patient's clinical circumstances. These findings underscore the value of personalized, clinician-guided care in helping patients make informed decisions about their family building journey," said Janet Choi, MD, Chief Medical Officer, Progyny. "The selection of Progyny's fertility research for presentation at this national forum highlights the relevance of evaluating how fertility care pathways affect patient experience and outcomes." About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. Progyny Inc. envision a world where everyone can realize their dreams of family and ideal health. Its outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Its benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com. For Further Information, Please Contact:

Yahoo Finance
Feb 27th, 2026
Progyny shares drop 22% on weak 2026 guidance despite Q4 revenue beating estimates

Progyny shares fell 22% after the fertility benefits company issued weak guidance for 2026, overshadowing strong fourth-quarter results. First-quarter 2026 revenue guidance of $325.5 million missed Wall Street expectations by 5.1%, whilst full-year adjusted earnings per share and EBITDA forecasts also disappointed analysts. Despite reporting fourth-quarter 2025 revenue of $318.4 million—up 6.7% year-on-year and beating expectations—and adjusted earnings per share of $0.48 that exceeded consensus by nearly 20%, investors focused on the weaker outlook, signalling concerns about future growth. The stock is down 32.1% year-to-date and trading 38.5% below its 52-week high of $28.42. Shares closed at $17.47.

Yahoo Finance
Feb 26th, 2026
Progyny posts record $1.29B revenue and $222M adjusted EBITDA in 2025, beating guidance by nearly $90M

Progyny, a fertility benefits provider, reported strong fourth-quarter results for 2025, with annual revenue reaching $1.29 billion and adjusted EBITDA of $222 million, both exceeding guidance by $90 million and $28 million respectively. The company generated record operating cash flow of $210 million, up 17% year-over-year. CEO Pete Anevski noted that 2025 marked the fourth consecutive quarter where revenue and adjusted EBITDA surpassed expectations. Both metrics grew double digits compared to 2024. The company provided financial outlook for 2026 during the earnings call, including anticipated client numbers, covered lives, and utilization rates. Progyny's management discussed the demand for its fertility and family-building solutions and its strategy for acquiring new clients whilst retaining existing ones.

Yahoo Finance
Feb 26th, 2026
Progyny Q4 earnings beat expectations with $318.4M revenue, projects up to $1.41B for 2025

Progyny, a New York-based provider of fertility and family building benefits, reported fourth-quarter earnings of $12.5 million, or 48 cents per share on an adjusted basis, surpassing Wall Street expectations of 38 cents per share. Revenue reached $318.4 million, exceeding analyst forecasts of $303.9 million. For the full year, the company posted profit of $58.5 million on revenue of $1.29 billion. Progyny expects first-quarter revenue between $319 million and $332 million, with earnings per share of 42 to 45 cents. The company projects full-year revenue of $1.36 billion to $1.41 billion, with earnings per share ranging from $1.83 to $1.95.

INACTIVE